NASDAQ:TRVI Trevi Therapeutics (TRVI) Stock Price, News & Analysis $2.95 -0.15 (-4.84%) (As of 09/6/2024 ET) Add Compare Share Share Today's Range$2.93▼$3.1050-Day Range$2.58▼$3.2552-Week Range$0.97▼$4.00Volume71,463 shsAverage Volume111,460 shsMarket Capitalization$214.14 millionP/E RatioN/ADividend YieldN/APrice Target$7.80 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Get Trevi Therapeutics alerts: Email Address Trevi Therapeutics MarketRank™ Stock AnalysisAnalyst RatingBuy3.17 Rating ScoreUpside/Downside164.4% Upside$7.80 Price TargetShort InterestBearish2.07% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.17Based on 15 Articles This WeekInsider TradingSelling Shares$98,285 Sold Last QuarterProj. Earnings GrowthDecreasingFrom ($0.47) to ($0.54) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.29 out of 5 starsMedical Sector463rd out of 910 stocksPharmaceutical Preparations Industry215th out of 426 stocks 3.6 Analyst's Opinion Consensus RatingTrevi Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.17, and is based on 5 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageTrevi Therapeutics has only been the subject of 4 research reports in the past 90 days.Read more about Trevi Therapeutics' stock forecast and price target. Previous Next 2.0 Short Interest Percentage of Shares Shorted2.07% of the outstanding shares of Trevi Therapeutics have been sold short.Short Interest Ratio / Days to CoverTrevi Therapeutics has a short interest ratio ("days to cover") of 6.6.Change versus previous monthShort interest in Trevi Therapeutics has recently increased by 16.28%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldTrevi Therapeutics does not currently pay a dividend.Dividend GrowthTrevi Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for TRVI. Previous Next 1.8 News and Social Media Coverage News SentimentTrevi Therapeutics has a news sentiment score of 0.17. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.55 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 15 news articles for Trevi Therapeutics this week, compared to 2 articles on an average week.Search InterestOnly 4 people have searched for TRVI on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added Trevi Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Previous Next 4.2 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Trevi Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $98,285.00 in company stock.Percentage Held by Insiders24.37% of the stock of Trevi Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions95.76% of the stock of Trevi Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Trevi Therapeutics' insider trading history. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Trevi Therapeutics are expected to decrease in the coming year, from ($0.47) to ($0.54) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Trevi Therapeutics is -8.68, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Trevi Therapeutics is -8.68, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioTrevi Therapeutics has a P/B Ratio of 3.24. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Trevi Therapeutics' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Paradigm PressKamala’s Dirty Election Move… RevealedAccording to former advisor to the CIA, the Pentagon and the White House Jim Rickards… Kamala and her puppet masters are planning this dirty election move… Click here now and learn how to prepare. About Trevi Therapeutics Stock (NASDAQ:TRVI)Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapy Haduvio for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC) conditions targeting the central and peripheral nervous systems. The company is developing Haduvio, an oral extended-release formulation of nalbuphine, which is in phase 2b Cough Reduction in IPF with nalbuphine ER (CORAL) clinical trial for treatment of chronic cough in patients with IPF; phase 2a Refractory Chronic Cough Improvement Via NAL ER (RIVER) clinical trial for reducing chronic cough in RCC patients; phase 2 clinical trial in patients with pruritus; phase 2b/3 clinical trial in patients with prurigo nodularis. It has a license agreement with Endo Pharmaceuticals Inc. to develop and commercialize products incorporating nalbuphine hydrochloride in any formulation. The company was incorporated in 2011 and is headquartered in New Haven, Connecticut.Read More TRVI Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart TRVI Stock News HeadlinesSeptember 6 at 9:32 AM | insidertrades.comInsider Selling: Trevi Therapeutics, Inc. (NASDAQ:TRVI) CEO Sells 10,981 Shares of StockSeptember 6 at 7:30 AM | marketbeat.comWhy Trevi Therapeutics Could Be a Triple-Bagger Biotech StockWall Street analysts see big potential upside for small-cap biopharma firm Trevi Therapeutics. So, what does the firm do and how does it stand out?September 7, 2024 | Paradigm Press (Ad)Kamala’s Dirty Election Move… RevealedAccording to former advisor to the CIA, the Pentagon and the White House Jim Rickards… Kamala and her puppet masters are planning this dirty election move… August 30, 2024 | insidertrades.comTrevi Therapeutics, Inc. (NASDAQ:TRVI) Director Sells $13,346.15 in StockAugust 17, 2024 | insidertrades.comThomas Sciascia Sells 18,660 Shares of Trevi Therapeutics, Inc. (NASDAQ:TRVI) StockSeptember 7 at 7:12 AM | yahoo.comCity of Rome says it is planning to limit numbers of tourists at the Trevi Fountain as it struggles with overtourismSeptember 6 at 9:08 PM | apnews.comRome could start charging tourists to visit the Trevi FountainSeptember 6 at 4:08 PM | cnn.comRome may limit tourist access to Trevi FountainSeptember 7, 2024 | Paradigm Press (Ad)Kamala’s Dirty Election Move… RevealedAccording to former advisor to the CIA, the Pentagon and the White House Jim Rickards… Kamala and her puppet masters are planning this dirty election move… September 6 at 4:08 PM | apnews.comA wish at Rome’s Trevi Fountain could soon cost more than the coin you tossSeptember 6 at 2:01 AM | washingtonpost.comRome floats plan to charge tourists at Trevi FountainSeptember 5 at 3:58 PM | skift.comRome Eyes Tourist Reservation System for Trevi FountainSeptember 5 at 10:58 AM | reuters.comRome considering limiting tourist access to Trevi FountainSeptember 4 at 4:05 PM | prnewswire.comTrevi Therapeutics Announces Oral Presentation on Data from Ph2a CANAL Trial at the European Respiratory Society Congress 2024September 2, 2024 | americanbankingnews.comTrevi Therapeutics, Inc. (NASDAQ:TRVI) Receives $7.80 Average Target Price from AnalystsSeptember 1, 2024 | msn.comHC Wainwright & Co. Initiates Coverage of Trevi Therapeutics (TRVI) with Buy RecommendationSeptember 1, 2024 | msn.comRaymond James Initiates Coverage of Trevi Therapeutics (TRVI) with Outperform RecommendationAugust 31, 2024 | americanbankingnews.comTrevi Therapeutics (NASDAQ:TRVI) Now Covered by Analysts at HC WainwrightSee More Headlines Receive TRVI Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Trevi Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings8/08/2024Today9/07/2024Next Earnings (Estimated)11/14/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:TRVI CUSIPN/A CIK1563880 Webwww.trevitherapeutics.com Phone(203) 304-2499FaxN/AEmployees20Year FoundedN/APrice Target and Rating Average Stock Price Target$7.80 High Stock Price Target$9.00 Low Stock Price Target$6.00 Potential Upside/Downside+164.4%Consensus RatingBuy Rating Score (0-4)3.17 Research Coverage6 Analysts Profitability EPS (Most Recent Fiscal Year)($0.34) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-29,070,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-49.92% Return on Assets-45.93% Debt Debt-to-Equity RatioN/A Current Ratio10.68 Quick Ratio10.68 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.91 per share Price / Book3.24Miscellaneous Outstanding Shares72,590,000Free Float53,270,000Market Cap$214.14 million OptionableOptionable Beta0.96 7 Stocks to Buy And Hold ForeverClick the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free Report Key ExecutivesMs. Jennifer L. Good (Age 59)Co-Founder, CEO, President & Director Comp: $781.85kDr. Thomas R. Sciascia M.D. (Age 71)Co-Founder & Chief Science Officer Comp: $530.48kDr. David J. Clark A.F.P.M. (Age 59)M.D., M.R.C.P., Chief Medical Officer Comp: $325.39kMs. Lisa Delfini (Age 54)Chief Financial Officer Mr. Christopher Galletta (Age 46)Controller & Chief Accounting Officer Katie McManusCommunications ManagerMr. Farrell Simon Pharm.D.Chief Commercial OfficerMs. Danine Summers (Age 66)Vice President of Medical Affairs More ExecutivesKey CompetitorsVanda PharmaceuticalsNASDAQ:VNDAProteostasis TherapeuticsNASDAQ:PTIVYNE TherapeuticsNASDAQ:VYNECara TherapeuticsNASDAQ:CARATectonic TherapeuticNASDAQ:TECXView All CompetitorsInsiders & InstitutionsJennifer L GoodSold 10,981 sharesTotal: $33,162.62 ($3.02/share)David P MeekerSold 4,555 sharesTotal: $13,346.15 ($2.93/share)Thomas SciasciaSold 18,660 sharesTotal: $51,501.60 ($2.76/share)The Manufacturers Life Insurance Company Bought 11,450 shares on 8/15/2024Ownership: 0.035%Logos Global Management LPBought 600,000 shares on 8/14/2024Ownership: 3.975%View All Insider TransactionsView All Institutional Transactions TRVI Stock Analysis - Frequently Asked Questions How have TRVI shares performed this year? Trevi Therapeutics' stock was trading at $1.34 at the beginning of the year. Since then, TRVI stock has increased by 120.1% and is now trading at $2.95. View the best growth stocks for 2024 here. How were Trevi Therapeutics' earnings last quarter? Trevi Therapeutics, Inc. (NASDAQ:TRVI) announced its quarterly earnings results on Thursday, August, 8th. The company reported ($0.12) earnings per share for the quarter, missing the consensus estimate of ($0.11) by $0.01. When did Trevi Therapeutics IPO? Trevi Therapeutics (TRVI) raised $70 million in an initial public offering (IPO) on Tuesday, May 7th 2019. The company issued 4,700,000 shares at $14.00-$16.00 per share. SVB Leerink, Stifel and BMO Capital Markets served as the underwriters for the IPO and Needham & Company was co-manager. Who are Trevi Therapeutics' major shareholders? Top institutional investors of Trevi Therapeutics include Rubric Capital Management LP (7.14%), Logos Global Management LP (3.98%), Ally Bridge Group NY LLC (2.09%) and Rosalind Advisors Inc. (1.98%). Insiders that own company stock include Tpg Gp A, Llc, David P Meeker, Thomas Sciascia, Jennifer L Good and Lisa Delfini. View institutional ownership trends. How do I buy shares of Trevi Therapeutics? Shares of TRVI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Trevi Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Trevi Therapeutics investors own include Trevena (TRVN), Diffusion Pharmaceuticals (DFFN), Fulcrum Therapeutics (FULC), Genocea Biosciences (GNCA), Marker Therapeutics (MRKR), VYNE Therapeutics (VYNE) and Akero Therapeutics (AKRO). This page (NASDAQ:TRVI) was last updated on 9/7/2024 by MarketBeat.com Staff From Our PartnersPerfect Crypto Buying Opportunity for 50 CentsWhen cryptos take a hit, the mom and pop investors run for the hills. But the top investors keep buying wit...Crypto 101 Media | SponsoredThe solution to fast food’s wage hike crisisShake Shack will be closing six California locations in response to the recent $20/hour minimum wage increase,...Deal Maker | SponsoredBiden’s Capital Gains Tax to Devastate Savings!Don't let the corrupt elites dictate your future—ACT NOW! This guide is your first step towards financial inde...Golden Crest | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredSay Goodbye to the US DollarThe warning signs are everywhere… According to experts, the United States Dollar is "as good as doomed." ...Sasco Gold LLC | SponsoredChina Stockpiling Gold “Like No Tomorrow”For 18 consecutive months, China’s central bank has increased its gold reserve. The country, with a populat...True Gold Republic | SponsoredThese 5 stocks could soar after November 4thHow to Trade this Crazy Election Year? Simple – Just Focus on These 5 stocks… Now available – a free report...StockEarnings | SponsoredTrump’s weapon lurks in abandoned AmericaUnemployment is sky-high, wages are at record lows. Addiction has overwhelmed these once thriving coal towns. ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Trevi Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Trevi Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free trvi Stock Alerts